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Abstract: Benzodiazepines are the most widely prescribed class of psychoactive drugs in 
current therapeutic use, despite the important unwanted side effects that they produce, such 
as sedation, myorelaxation, ataxia, amnesia, and ethanol and barbiturate potentiation and 
tolerance. They exert their therapeutic effects via binding to the benzodiazepine binding site 
of gamma-aminobutyric acid (GABA) type A receptors, and allosterically modulating the 
chloride flux through the ion channel complex. First isolated from plants used as tranquilizers 
in folkloric medicine, some natural flavonoids have been shown to possess selective affinity 
for the benzodiazepine binding site with a broad spectrum of central nervous system effects. 
Since the initial search for alternative benzodiazepine ligands amongst the flavonoids, a list 
of successful synthetic derivatives has been generated with enhanced activities. This review 
provides an update on research developments that have established the activity of natural and 
synthetic flavonoids on GABA type A receptors. Flavonoids are prominent drugs in the treat-
ment of mental disorders, and can also be used as tools to study modulatory sites at GABA type 
A receptors and to develop GABA type A selective agents further.
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Flavonoids
Flavonoids may have existed in nature for almost one billion years, and over 9000 
chemically unique flavonoids have been identified in plant sources. These compounds 
are low molecular weight substances, found in all vascular plants, and are phenylben-
zopyrones (Figure 1) with an assortment of basic structures.
Flavonoids occur as aglycones, glycosides, and methylated derivatives. In plants, 
flavonoid aglycones occur in a variety of structural forms. For convenience, the rings 
are labeled A, B, and C (Figure 1). The individual carbon atoms are based on a num-
bering system which uses ordinary numerals for A and C, and “primed” numerals 
for the B ring. The different ways of closing this ring associated with the different 
oxidation degrees of ring A define the various classes of flavonoids. Most flavonoids 
occur in natural association with sugar in conjugated form and, within any one class, 
may be characterized as, eg, monoglycosidic or diglycosidic. The glycosidic linkage 
is normally located at position 3 or 7 and the carbohydrate unit can be L-rhamnose, 
D-glucose, glucorhamnose, galactose, or arabinose.1 The chemical diversity, size, 
three-dimensional shape, and physical and biochemical properties of flavonoids allow 
them to interact with targets in different subcellular locations to influence biological 
activity in plants, animals, and microbes.2
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Apart from being important dietary components, many 
therapeutic benefits of flavonoids are known in animal 
 systems. Flavonoids have antioxidant, antiproliferative, 
antitumor, anti-inflammatory, and proapoptotic activities, and 
some molecular targets have been identified.3–7 The health-
promoting effects of flavonoids may relate to interactions 
with key enzymes, signaling cascades involving cytokines 
and transcription factors, or antioxidant systems.8
Because flavonoids can be found ubiquitously in 
plants, they are major constituents of a variety of fruit and 
 vegetables, beverages, such as tea and wine, and seeds such as 
cocoa beans and grape seeds. Flavonoids undergo  extensive 
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Figure 1 Chemical structures of some representative flavonoids.
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biotransformation and conjugation that occur during their 
absorption from the gastrointestinal tract, in the liver, and 
finally in cells.9–11 Dietary flavonoids are substrates for phase I 
and phase II enzymes in the small intestine and liver. They are 
deglycosylated and metabolized into glucuronides, sulfates, 
and O-methylated derivatives.12
Flavonoid absorption from the intestine occurs by sev-
eral different pathways. Flavonoid aglycones can be easily 
absorbed into the intestinal cells because their lipophilicity 
facilitates their passage across the mucosal phospholipid 
bilayer of cells. Lactase phlorizin hydrolase has a crucial 
role in the absorption of flavonoids bearing β-glycoside 
linkages.13 On the other hand, flavonoid monoglycosides 
can be transported by the sodium glucose transporter-114,15 
on the brush border membrane of intestinal cells. Most fla-
vonoid glycosides entering enterocytes are deglycosylated 
by β-glucosidases, namely, broad-specificity cytosolic 
β-glucosidase.16 The flavonoids appear to be subjected to 
glucuronidation, sulfation, and methylation in the intestinal 
epithelial cells before entering circulation.17 The flavonoid 
conjugates then gain access into hepatocytes where they 
are further methylated, glucuronidated, or sulfated.18 These 
flavonoid conjugates are excreted into the urine and also 
into bile fluid, thereby returning to the intestinal lumen.19 
Subsequently, they may be reabsorbed again, mainly in 
the large intestine. Further metabolism occurs in the colon, 
where enzymes of the gut microflora induce the breakdown 
of flavonoids to phenolic acids which may undergo absorp-
tion and be further metabolized in the liver.11,20 The present 
review focuses on advances in our knowledge pertaining to 
the action of flavonoids on the central nervous system, more 
precisely their effect on gamma amino butyric acid (GABA) 
type A receptors.
GABA type A receptor
Neuropharmacology is based simply on the fundamental 
balance between chemical excitation and inhibition. These 
processes are indispensable in the networks of neurons, 
and all neurons have receptors for inhibitory and excitatory 
neurotransmitters. The GABA system is one of the mecha-
nisms that takes care of chemical inhibition in the brain, and 
has been widely used for pharmacological modulation of 
brain function. Most brain neurons express GABA type A 
receptors, which are considered to be the most important 
for pharmacological modulation. These receptors are het-
eropentameric GABA-gated chloride channels belonging 
to the Cys-loop ligand-gated ion channel superfamily that 
also includes the nicotinic acetylcholine receptors, glycine 
receptors, and 5-HT
3
 receptors.21,22 The subunits of all these 
receptors share a common ancestral structure. In addition 
to the rapid actions of GABA via GABA type A receptors, 
GABA also modulates neural activity, albeit on a slower time 
scale, via activation of GABA type A receptors belonging 
to the G protein-coupled receptor superfamily. GABA type 
A receptor subunits are encoded by 19 different genes that 
have been grouped into eight subclasses based on sequence 
homology (α1–6, β1–3, γ1–3, δ, ε, θ, π, ρ1–3). Alternative 
splicing contributes to additional receptor diversity.23,24 
Knowing the number of subunits and potential combina-
tions, the quantity of possible receptor subtypes could be 
enormous. However, only 11 structurally and functionally 
distinct receptor subtypes have been conclusively identified 
and are reasonably abundant in at least parts of the brain. 
They represent combinations of 2α and 2β subunits, together 
with a single γ2 or δ subunit. A further 15 receptor subtypes 
exist with high probability and a more limited distribution.25 
These numbers do not account for additional heterogeneity 
based on two different types of α or β subunits in one receptor 
complex,26 or due to alternative splicing of subunits. GABA 
type A receptors with different subunit compositions exhibit 
different pharmacology and channel gating properties, are 
differentially expressed during development and in the adult 
brain, accumulate at different neuronal cell surfaces, and are 
subject to differential regulation by extracellular cues.27
GABA type A receptors can be allosterically modulated 
by benzodiazepines, barbiturates, steroids, anesthetics, anti-
convulsants, and many other drugs, the number of which is 
constantly increasing.28,29 These compounds do not interact 
directly with the GABA binding site, but exert their actions 
by binding to allosteric sites at GABA type A receptors that 
influence the binding properties of other binding sites present 
on these receptors and so modulate GABA-induced chloride 
ion influx (Figure 2).
Benzodiazepines are anticonvulsive, sedative-hypnotic, 
and anxiolytic compounds in clinical use. They produce allos-
teric changes that enhance the action of GABA on GABA 
type A receptors, increasing the GABA-induced frequency of 
opening of the chloride channels and the apparent affinity of 
the receptor for GABA. Benzodiazepines represented a major 
advance in psychopharmacology in the 1960s and have been 
some of the most widely prescribed drugs. They are sedating 
and, more importantly, produce physical dependence, such 
that significant withdrawal symptoms are observed on treat-
ment cessation. In addition, benzodiazepines can be drugs of 
abuse. This inspired the development of subtype-selective 
agonists, which might retain the beneficial effects of an 
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antianxiety and anticonvulsant profile, while no longer being 
sedative, ataxic, or having dependence liability.30
The location of the benzodiazepine binding site at the 
α and γ subunit interface indicates that the pharmacology of 
the benzodiazepine receptor subtypes is mainly determined 
by the α and γ isoforms forming this site, whereas β subunits, 
although needed to construct a channel, do not greatly affect 
the sensitivity of the GABA type A receptors to benzodiaz-
epine ligands. The traditional benzodiazepine agonists (such 
as diazepam) are active at GABA type A receptors containing 
a γ subunit, a β subunit, and one of the α subunits, ie, α 1, 2, 
3, or 5.31 The benzodiazepine-sensitive GABA type A recep-
tors can be further subdivided, in that receptors containing 
the α1 subunit have a higher sensitivity to a subpopulation 
of benzodiazepine ligands, such as quazepam or zolpidem 
(an imidazopyridine).28,31,32 Furthermore, receptors contain-
ing the α2 or α3 subunit have an intermediate affinity for 
zolpidem, whereas those containing α5 have very low affinity 
for this drug.
Receptors containing the α4 or α6 subunits, together with 
β and γ2, do not bind the traditional benzodiazepine agonists, 
including zolpidem, but demonstrate high affinity for some 
ligands, such as flumazenil and Ro15-4513, or bretazenil.28 
Both the potency and efficacy for benzodiazepine ligands 
depend on the nature of the α subunit.
The benzodiazepine binding site ligands so far identified 
do not distinguish well between the α2 and α3 or between the 
α4 and α6 subunits. However, all four subunits can produce 
functional channels in vitro when coexpressed with other 
subunits, and their differential distribution in the brain sug-
gests that they modulate different behavioral circuitry.
The functional relevance of the receptor subtypes was 
revealed using a combined molecular genetic and pharma-
cological approach.33,34 Mouse lines were generated in which 
each of the benzodiazepine-sensitive GABA type A receptors 
(containing α1, α2, α3, or α5 subunits) was rendered insensi-
tive to diazepam by a point mutation in the benzodiazepine 
binding site (eg, α1 H101R).35 A comparison of drug-induced 
behavioral responses in the mutated and wild-type mice then 
allowed identification of diazepam effects that were miss-
ing or reduced in the mutant mice. It was demonstrated that 
α1βγ2 receptors mediate the sedative, antegrade amnestic, 
and some anticonvulsant actions of diazepam.35,36 The anxi-
olytic activity of diazepam is mediated mostly by GABA 
Benzodiazepine binding site
Subunits involved: α1,2,3,5 β and γ2
Agonist: diazepam, flunitrazepam
Antagonist: flumazenil
Partial agonist: bretazenil
Inverse agonist: β-carbolines
Agonist: GABA
Antagonist: bicuculline
Partial agonist: Imidazole-4-acetic acid
Intracellular
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Cl−
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Subunits involved: α and β
Antagonists:
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Figure 2 Schematic model of the GABA type A receptors. 
Notes: As shown in this model, GABA type A receptors exhibit a GABA binding site that mediates the effects of agonists and competitive antagonists, a Cl- channel, and 
modulatory binding sites for benzodiazepiness, barbiturates, picrotoxin, and anesthetic steroids. The model is not meant to reflect the subunit structure of the receptor.
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type A receptors composed of α2βγ2 subunits37 and also 
by α3 GABA type A receptors.38 This allowed sedation and 
anxiolysis to be separated in molecular terms, mediated by 
different pathways that were characterized by the presence of 
α1- and α2-GABA type A receptors, respectively. The α2βγ2 
receptors are also implicated in some of the muscle relaxant 
activities of diazepam.37 Receptors containing the α3 subunit 
seem to mediate the antiabsence effects of  clonazepam. The 
α5βγ2 receptors seem to influence learning and memory.39
The action of benzodiazepines can be blocked by 
 flumazenil. However, flumazenil-insensitive positive modula-
tion of GABA type A receptors has been described in receptors 
lacking a γ subunit by benzodiazepines at µM  concentrations. 
It was found that recombinant α1β1 GABA type A recep-
tors from the rat brain were sensitive to potentiation by 
benzodiazepine binding site ligands, with both diazepam and 
flumazenil acting as positive modulators.40 It was also found 
that classical benzodiazepines produce biphasic potentiation 
at rat recombinant α1β2γ2 GABA type A receptors via two 
distinct mechanisms.41 This biphasic potentiation is believed 
to be mediated via two sites, referred to as high-affinity and 
low-affinity benzodiazepine binding sites. Both sites are 
present on receptors composed of α1β2γ2 GABA type A 
subunits, and low affinity potentiation can be selectively 
observed at receptor combinations lacking a γ subunit, such 
as α1β2 GABA type A receptors. Furthermore, low affinity 
potentiation at both receptor combinations is insensitive to 
flumazenil.
Natural flavonoids as GABA  
type A receptor ligands
Nature provides science and society with a virtually unlim-
ited supply of structurally diverse and biologically active 
molecules. While some are directly useful in commercial 
applications, others are valuable for studying and understand-
ing biological phenomena at the molecular level. Flavonoids 
are only a modest example.
The first report of flavonoids as central nervous system 
ligands was described by Roche researchers. In their study, 
they were looking for the presence of “diazepam-like” 
endogenous ligands in bovine urine, in which they isolated 
a few isoflavan derivatives: (S-7,4′-dihydroxyisoflavan 
(equol); dl-3′,7-dihydroxyisoflavan; dl-4′-hydroxy-
7-methoxyisoflavan; dl-7-hydroxy-4′-methoxyisoflavan; 
7-hydroxy-4′-methoxyisoflavone (formononetin); and 
4′-hydroxy-7-methoxyisoflavone; 3′,7-dihydroxyisoflavone) 
(Figure 3) with low affinity for the benzodiazepine binding 
site.42 Some years later, using a radioreceptor-guided 
purification protocol, we were able to isolate one of these 
isoflavan ligands (equol) from bovine rumen contents, an 
important natural source of “diazepam-like” compounds.43 
These isoflavans were most probably derived from plant 
sources in the bovine diet.
The next valuable antecedent in this story of flavonoids 
active in the central nervous system was the discovery of 
the biflavonoid, amentoflavone (Figure 4) as a high affin-
ity ligand for the benzodiazepine binding site. This natural 
compound (Karmelitter Geist) was isolated from an extract 
of several commercially available medicinal plants and used 
to treat nervous disorders.44
Amentoflavone is one of the most potent flavonoids in 
displacing benzodiazepine binding to rat brain membranes, 
but is inactive in vivo. It binds, in vitro, in a mixed-type 
competitive and noncompetitive manner to brain receptors, 
with an affinity comparable with that of diazepam. Studies 
on subtype specificity showed that amentoflavone had little 
or no affinity for α4-containing or α6-containing receptors.45 
This biflavonoid can be extracted from Ginkgo biloba but 
removed from herbal preparations such as EGb 761.46 Using 
a functional assay employing recombinant GABA type A 
receptors expressed in oocytes, amentoflavone has been 
shown to be a weak negative allosteric modulator of GABA 
action, acting independently of classical flumazenil-sensitive 
benzodiazepine-modulatory sites.46 It was also reported that 
amentoflavone influences a variety of G protein-coupled 
receptors for serotonin, dopamine, and opioids at nM concen-
trations, while having no effect on the binding of muscimol, 
a GABA type A agonist to GABA type A receptors.47
Since then and contemporary with the work described 
above, research in our laboratories was devoted to the iden-
tification of natural ligands for the benzodiazepine binding 
site in plants. In particular, we were looking for benzodiaz-
epines or benzodiazepine-like compounds, and the discovery 
of the properties of amentoflavone44 drove our investigation 
to similar ligands in plants known to contain flavonoids and 
we also extended this study to other plants traditionally used 
as tranquillizers.48–51
In vivo and in vitro studies with the principal flavonoid 
and flavonol derivatives (Table 1) have clarified their pharma-
cological actions on the binding of benzodiazepines. The first 
monoflavonoid described as a specific ligand for the benzo-
diazepine binding site was chrysin (5,7-dihydroxyflavone).52 
This compound, isolated from Passiflora caerulea L, is a 
selective and competitive inhibitor of [3H]flunitrazepam 
binding to the benzodiazepine binding site. Chrysin is almost 
equipotent to diazepam as an anxiolytic, but does not exhibit 
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sedative or myorelaxant effects.53 It was postulated that this 
natural monoflavonoid is a partial agonist of the central 
benzodiazepine binding site. Additionally, both intraperi-
toneal and oral administration of chrysin in mice produced 
a significant hyperalgesic effect in the tail-immersion test 
that involved GABA type A receptors, as does  flumazenil, 
a specif ic antagonist for the benzodiazepine binding 
site; bicuculline, a GABA type A receptor antagonist and 
picrotoxin, a chloride channel blocker, could antagonize the 
hyperalgesia of chrysin.54
The dried flower heads of Matricaria recutita L are used 
in folk medicine to prepare a spasmolytic and sedative tea. 
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Figure 3 Molecular structures of (A) flavans and (B) isoflavones.
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The fractionation of the aqueous extract of this plant led to the 
detection of several fractions with significant affinity for the 
benzodiazepine binding site and to the isolation and iden-
tification of apigenin (5,7,4′-trihydroxyflavone).  Apigenin 
competitively binds to the benzodiazepine binding site of 
the GABA type A receptor, has clear anxiolytic activity in 
mice when administered intraperitoneally, without showing 
evidence of sedation or muscle relaxant effects at doses similar 
to those used for classical benzodiazepines and no anticonvul-
sant action.55 However, other studies, performed in rats, found 
that apigenin fitted the profile of an inverse benzodiazepine 
agonist and was sedative and mildly proconvulsant, but not 
anxiolytic.56,57 Meanwhile, others reported that apigenin fitted 
the profile of a benzodiazepine antagonist.58 The discrepancies 
between the in vitro and in vivo results obtained for apigenin 
may be due to its in vivo metabolism or the use of different 
Table 1 Flavone and flavonol derivatives
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Figure 4 Molecular structures of amentoflavone and isoliquiritigenin.
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species, ie, rats or mice, because mice have higher baseline 
levels of anxiety. Thus, apigenin appears to have diverse 
effects at the benzodiazepine binding site and the nature 
of these effects is unclear. Overall, it seems that the effects 
of apigenin on GABA type A receptors are complex and 
involve both flumazenil-sensitive and flumazenil-insensitive 
components, and that other receptors could be involved in the 
behavioral effects of this drug.59,60
The flavonoids, kaempferol (3,5,7,4′-tetrahydroxyflavone) 
and cirsiliol (5,3′,4′-trihydroxy-6,7-dimethoxyflavone), iso-
lated from Tilia tomentosa Moench and Salvia guaranitica, 
respectively, exhibited a very low affinity for the benzodi-
azepine binding site and were devoid of anxiolytic actions 
by the intraperitoneal route. However, cirsiliol produced 
sedation in mice as measured by the holeboard test and had 
thiopental-potentiating effects.61–63 Recently, a comparative 
study of the anxiolytic activity of the flavonols, kaempferol, 
quercetin, (3,5,7,3′,4′-pentahydroxyflavone), and myricetin 
(3,5,7,3′,4′,5′-hexahydroxyflavone) in the elevated plus-maze 
after oral and intraperitoneal administration in mice showed 
that only kaempferol and quercetin were active after oral 
administration.64 The anxiolytic activity of kaempferol was 
also partially antagonized by concomitant administration 
of flumazenil.65 No anxiolytic effects were observed when 
kaempferol and quercetin were given via the intraperitoneal 
route. It was hypothesized that flavonoids could act as pro-
drugs which are transformed into their active hydroxyphenyl-
acetic acid metabolites by intestinal microflora.64
Wogonin (5,7-dihydroxy-8-methoxyflavone), isolated 
from Scutellaria baicalensis Georgi, a Chinese medicinal 
herb, has been reported to have anxiolytic and anticonvul-
sant activity in orally treated mice, that could be blocked by 
coadministration of flumazenil,66,67 with no sedative or myo-
relaxant effects. Another flavonoid isolated from this herb, 
oroxylin A (5,7-dihydroxy-6-methoxyflavone), inhibits [3H]
flunitrazepam binding and, orally administered in mice, acts 
as a neutralizing allosteric modulator blocking the anxiolytic, 
myorelaxant, and motor incoordination effects but not the 
sedative and anticonvulsant effects elicited by diazepam, a 
full benzodiazepine agonist.68
Dinatin, a synonym of hispidulin (4′,5,7-trihydroxy-6-
methoxyflavone) and skrofulein, a synonym of cirsimaritin 
(4′,5-dihydroxy-6,7-dimethoxyflavone), two flavones iso-
lated from the medicinal plant from Artemisia herba-alba 
Asso, were found to be antagonists or weak partial agonists 
of the benzodiazepine binding site, and inhibited the binding 
of [3H] diazepam to rat brain membranes in vitro by a mixed 
competitive and noncompetitive mechanism.69 Hispidulin, 
the 6-methoxy derivative of apigenin, was further isolated, 
together with apigenin from Salvia officinalis (sage) using 
benzodiazepine binding site assay-guided fractionation.70 
This flavone has been demonstrated to have anticonvulsant 
activity in a model of epilepsy in seizure-prone Mongolian 
gerbils and to cross the blood-brain barrier.71 Unlike apigenin, 
hispidulin has been shown to act as a positive allosteric modu-
lator of α1,3,5,6β2γ2S GABA type A receptor subtypes.71
Daidzein (4′,7-dihydroxyisoflavone) and its 8-C 
 glycoside, puerarin (7,4′-dihydroxy-8-C-glucosylisoflavone) 
(Figure 3), two isoflavones isolated from Puerariae radix, 
a Chinese traditional herb used to treat drunkenness and 
alcoholic addiction, were found to inhibit the binding of [3H]
flunitrazepam to rat brain membranes.72
Leptospermum scoparium Forst contains the lipophilic 
flavonoids, 5,7-dimethoxyflavone, 5,7-dimethoxy-6-
methylflavone, 5-hydroxy-7-methoxy-6-methylflavone, and 
5-hydroxy-7-methoxy-6,8-dimethylflavone, which interact 
specifically with the benzodiazepine binding site. A dry 
extract of the tincture prepared from this plant and contain-
ing these flavones induced sedative and anxiolytic effects 
in rats.73
Another apigenin derivative was further reported as 
a benzodiazepine binding site ligand. 6-Methylapigenin 
(4′,5,7-dihydroxy-6-methylflavone), the 6-methyl derivative 
of apigenin, was isolated from the roots and rhizomes of 
Valeriana wallichii, a known sedative medicinal plant, and 
inhibited [3H]flunitrazepam binding at 0.5 µM in a manner 
suggesting it may be a positive modulator of GABA type A 
receptors.74 6-Methylapigenin induced anxiolytic effects 
in mice treated by the intraperitoneal route and was able 
to potentiate the sleep-enhancing properties of hesperidin 
(hesperetin 7-rhamnoglucoside), a flavanone glycoside also 
isolated from V. wallichii and Valeriana officinalis.75
Epigallocatechin gallate (EGCG, (-)-cis-3,3′,4′,5,5′,7-
hexahydroxy-flavane-3-gallate) (Figure 5), a flavanol ester 
and a constituent of green tea, was demonstrated to exert 
dose-dependent anxiolytic, sedative-hypnotic, and amnesic 
activities after acute intraperitoneal administration in mice, 
that could be mediated, at least in part, by GABA type A 
receptors.76,77 In vitro, this flavonoid could also inhibit acti-
vation by GABA and enhance the modulatory action of 
diazepam on activation by GABA of recombinant human 
α1β2γ2L GABA type A receptors expressed in Xenopus 
laevis oocytes.78
Some natural and synthetic flavanones have been inves-
tigated in benzodiazepine binding studies. Examples are 
eriodictyol (5,7,3′,4′-tetrahydroxyflavanone), hesperetin 
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(5,7,3′-trihydroxy-4′-methoxyflavanone), and flavanone 
itself (Figure 5), among others. All of them were found to 
be inactive or only weakly active in vitro.73,79,80 However, it 
was recently reported that dihydromyricetin (3,5,7,3′,4′,5′-
hexahydroxyflavanone) (Figure 5) is a positive modulator 
of GABA type A receptors at benzodiazepine binding sites 
that competitively inhibited [3H]flunitrazepam binding with 
moderate affinity. Dihydromyricetin is a flavonoid compo-
nent of Hovenia dulcis, an herbal medicine listed among 
the premier antihangover plants in China that ameliorates 
alcohol-induced liver injuries and relieves hangover. This 
flavanone, administered intraperitoneally in rats, is highly 
effective in counteracting acute alcohol intoxication, alcohol 
exposure/withdrawal-induced GABA type A receptor plastic-
ity and alcohol withdrawal syndrome symptoms, as well as 
reducing excessive alcohol consumption.81
Luteolin (5,7,3′,4′-tetrahydroxyflavone) is a flavonoid 
aglycon found in a wide variety of plants. It has been reported 
to displace [3H]flunitrazepam from the benzodiazepine bind-
ing site in vitro, with low affinity, and it has demonstrated 
anxiolytic-like effects administered orally in mice. Despite the 
need to analyze the interaction of luteolin with the benzodiaz-
epine binding site further, these results suggested that by itself 
this interaction does not seem to explain the results observed 
in vivo fully, thus prompting renewed interest in the analysis 
of possible interactions with other receptors.82,83
Baicalein (5,6,7-trihydroxyflavone) and baicalin 
(baicalein 7-O-D-glucuronide), together with wogonin 
and oroxylin A, are the major bioactive components in 
S. baicalensis. Baicalin was reported to induce an anxiolytic-
like effect devoid of sedation and myorelaxation in mice when 
administered orally, acting via the benzodiazepine binding 
site. It showed significant preference for α2-containing and 
α3-containing subtypes compared with α1-containing and 
α5-containing subtypes in whole-cell patch clamp studies.84 
Baicalein and baicalin also showed neuroprotective and 
anticonvulsant effects in rats injected intraperitoneally 
and the anticonvulsant effect of baicalein was inhibited 
by flumazenil.85 Other authors reported that baicalein 
showed anxiolytic and sedative effects when administered 
via the intracerebroventricular route in mice, and that this 
central effect were blocked by pentylenetetrazole but not 
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by flumazenil. Therefore, they concluded that the in vivo 
actions of baicalein could be mediated by GABAergic 
nonbenzodiazepine binding sites.86 Another naturally 
occurring flavonoid isolated from S. baicalensis, ie, K36 
(5,7,2′-trihydroxy-6,8-dimethoxyflavone), exhibited 
the highest affinity for the benzodiazepine binding site, 
comparable with that of the synthetic anxiolytic, diazepam 
(Ki 6.05 nM). In electrophysiological experiments, K36 
potentiated currents mediated by the recombinant rat α1β2γ2 
GABA type A receptor expressed in X. laevis oocytes and this 
enhancement was demonstrated to act via the benzodiazepine 
binding site. Oral administration of K36 produced significant 
benzodiazepine binding site-mediated anxiolysis in the 
mouse elevated plus-maze, which was abolished upon 
coadministration of flumazenil. Sedation, myorelaxation, and 
motor incoordination were not observed. Structure-activity 
relationships utilizing synthetic flavonoids on the flavone 
backbone supported that 2′-hydroxyl-substitution is a critical 
moiety on flavonoids with regard to benzodiazepine binding 
site affinity.87
Chalcones are unique in the flavonoid family in lacking 
a heterocyclic C ring and exhibit the basic structure with 
two benzene rings linked through an α, β-unsaturated car-
bonyl group. Isoliquiritigenin (2′,4′,4′-trihydroxychalcone) 
(Figure 4) is a chalcone compound found in Glycyrrhiza 
uralensis (licorice), Allium ascalonicum, Sinofranchetia 
chinensis, Dalbergia odorifera, and Glycine max L. This 
chalcone showed anxiolytic effects in the elevated plus-maze 
test administered intraperitoneally in mice and rats. It also 
significantly potentiated pentobarbital-induced sleep in a 
dose-dependent manner and this effect was fully inhibited 
by flumazenil. The binding affinity of isoliquiritigenin was 
0.453 µM and it potentiated GABA-evoked currents on iso-
lated dorsal raphe neurons. Thus, these results suggest that 
this natural chalcone produces hypnotic effects by positive 
allosteric modulation of the benzodiazepine binding site of 
the GABA type A receptor.88,89
Synthetic derivatives: importance 
of 6-substitutions on the flavonoid 
nucleus
The results obtained with natural flavonoids encouraged us 
to attempt to increase their potency as benzodiazepine bind-
ing site ligands by introducing electronegative substituents 
into their molecules, because this feature was shown to be 
essential for the activity of the classical benzodiazepines.90
Based on structure-activity relationship studies, incorpo-
ration of electronegative groups into the C6 and C3′ on the 
flavone backbone was found to yield significant increases 
in the binding affinities for the benzodiazepine binding 
site.79,80 It was also shown that 2′-hydroxyl was also a 
critical  moiety on flavonoids with regard to benzodiazepine 
 binding.87 These have guided the generation of several syn-
thetic flavonoids with high benzodiazepine binding affinity 
and in vivo activity, and further quantitative structure-activity 
relationship studies resulted in the development of several 
pharmacophore models.
The first report of an active derivative of flavone was 
a brominated compound, 6-bromoflavone. This derivative 
showed a high affinity for the benzodiazepine binding site 
and resulted in a competitive ligand for these receptors. Its 
pharmacological profile, when administered intraperitoneally 
in mice, was quite similar to that observed for diazepam.91 
The data to date strongly suggest that 6-bromoflavone is 
a full agonist of the central benzodiazepine binding site. 
6-Bromo-3′-nitroflavone exhibited a different affinity for 
benzodiazepine binding site subtypes containing the α1 
and α2/3 receptors. The plus-maze test revealed that it 
is anxiolytic at intraperitoneal doses of 10–300 µg/kg in 
mice.92,93 In contrast, 6-chloro-3′-nitroflavone and 6-methyl-
3′-bromoflavone had no anxiolytic effects, and their phar-
macological profile manifested antagonistic actions at the 
benzodiazepine binding site.94,95 In turn, 6,3′-dibromoflavone 
and 6-nitro-3′-bromoflavone had anxiolytic effects when 
administered intraperitoneally in mice, with partial agonistic 
behavior (Table 2).96
The most active anxiolytic flavone derivative prepared 
in our laboratory was 6,3′-dinitroflavone. A 1–30 µg/kg 
intraperitoneal injection of this compound in mice produced 
 anxiolytic-like effects. It is at least 30 times more potent 
by weight than diazepam and 3000 times more potent than 
 flavone. It also has a very favorable separation index, being the 
separation index the ratio between the minimal sedative dose 
and the maximal anxiolytic one. Its magnitude qualifies the 
pharmacological selectivity of the compound.97,98  Inhibition 
of [3H]flunitrazepam binding to recombinant GABA type A 
receptors in transiently transfected HEK293 indicated that 
6,3′dinitroflavone exhibited the highest affinity for GABA 
type A receptors composed of α1β2γ2 subunits and a 
2–20-fold lower affinity for homologous receptors contain-
ing α2, α3, or α5 subunits. 6,3′-dinitroflavone did not elicit 
currents in the absence of GABA in X. laevis oocytes express-
ing any of the recombinant GABA type A receptors tested. 
However, 6,3′-dinitroflavone was slightly able to modulate 
GABA-elicited currents, similar to other benzodiazepine 
site ligands.99
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Table 2 Synthetic flavone derivatives
O
OR5
R6
R7
R8
R3
R6'
R5'
R3'
R2' R4'
Flavonoid derivative Kia (μM) GABA  
ratiob
Pharmacological profile
Predictedb In vivo In vitro
6-bromo 0.07091 1.6–2.0 Full agonist Full agonist Positive modulator101
6-methyl 0.125112 ND ND ND Positive modulator (at sites independent of 
flumazenil-sensitive benzodiazepine binding site)103
6-chloro 0.164113 ND ND Antagonist101 Neutralizing modulator101
6-nitro 0.275113 ND ND ND ND
6-hydroxy 0.580112 ND ND Partial agonist102 Positive modulator102
6-methoxy 0.860112 ND ND ND ND
6-fluoro 4.5113 ND ND Antagonist102 Neutralizing modulator102
Flavone 191 ND ND Partial agonist ND
6-bromo-3′-nitro 0.00192 1.38 Partial agonist Partial agonist93 ND
6-methyl-3′-nitro 0.0056114 0.72 Inverse agonist ND ND
6-chloro-3′-nitro 0.008113 1.16 Antagonist Antagonist95 ND
6,3′-dinitro 0.02697 1.30 Partial agonist Partial agonist98 Low efficacy modulator99
6-fluoro-3′-nitro 0.180113 ND ND ND ND
3′-nitro 0.285113 ND ND ND ND
6,3′-dibromo 0.019113 1.29 Partial agonist Partial agonist96 ND
6-methyl-3′-bromo 0.01394 1.03 Antagonist Antagonist94 ND
6-chloro-3′-bromo 0.023115 1.10 Antagonist ND ND
6-nitro-3′-bromo 0.025113 1.19 Partial agonist Partial agonist96 ND
6-fluoro-3′-bromo 0.236115 ND ND ND ND
3′-bromo 0.413113 ND ND ND ND
6-hydroxy-3′-bromo 1116 ND ND ND ND
6-methoxy-3′-bromo 1116 ND ND ND ND
6-bromo-3′-chloro 0.017115 1.23 Partial agonist ND ND
6,3′-dichloro 0.023115 1.10 Antagonist ND ND
6-fluoro-3′-chloro 0.199115 ND ND ND ND
3′-chloro 0.614113 ND ND ND ND
6,3′-dimethyl 29114 1.63 Full agonist ND ND
6-bromo-3′-methyl 0.154116 ND ND ND ND
6,3′-dimethyl 0.208116 ND ND ND ND
3′-methyl 10116 ND ND ND ND
3′-methoxy 2.4115 ND ND ND ND
3′-fluoro 3.55115 ND ND ND ND
6-bromo-3′-fluoro 0.042115 0.97 Antagonist-inverse  
agonist
ND ND
6-bromo-3′-methoxy 0.609115 ND ND ND ND
6-chloro-3′-fluoro 0.117115 ND ND ND ND
6-chloro-3′-methoxy 0.848115 ND ND ND ND
6,3′-difluoro 0.920115 ND ND ND ND
6-fluoro-3′-methoxy 2.5115 ND ND ND ND
3-bromo .7591 ND ND ND ND
6,3-dibromo .7591 ND ND ND ND
3-bromo-3′-nitro .20113 ND ND ND ND
(Continued)
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Relatively extensive pharmacological studies on our syn-
thetic flavonoids have been conducted by other authors, and 
the results obtained confirmed and extended our findings.100,101 
Recently, flavone analogs, each varying only in the 6-position 
substituent, were compared. Whole-cell patch-clamp and 
animal behavior experiments demonstrated 6-bromoflavone 
to be a positive modulator at GABA type A receptors, act-
ing via a flumazenil-sensitive high-affinity benzodiazepine 
binding site. In contrast, 6-fluoroflavone and 6-chloroflavone 
were found to be neutralizing modulators. In patch-clamp 
studies, 6-hydroxyflavone displayed a significant preference 
for α2-containing and α3-containing subtypes, which were 
thought to mediate the anxiolytic effect, compared with α1- 
and α5-containing subtypes expressed in HEK 293T cells. 
In mice, 6-hydroxyflavone exhibited anxiolytic-like effects 
unaccompanied by the sedative, cognitive impairment, myo-
relaxant, motor incoordination, and anticonvulsant effects 
commonly associated with classical benzodiazepines.102 
In addition, in vitro electrophysiological and in vivo ani-
mal experiments showed that 2′-hydroxyflavone was an 
antagonist, different in efficacy from its structural analog, 
6,2′-dihydroxyflavone, a negative modulator of GABA type A 
receptors. The fact that flavone derivatives differing only 
at position 6 showed drastically different pharmacological 
properties clearly points to 6-substitution being an important 
determinant of efficacy. All the results suggest that a large 
width of the first atom on the 6-substituent favors a high 
binding affinity of the 6-substituted flavone, whereas a large 
overall volume of the 6-substituent favors positive modula-
tor activity, which could be modified by, eg, 2′-hydroxyl 
substitution.101
6-Methylflavone was found to be a positive allosteric 
modulator at α1β2γ2L and α1β2 GABA type A receptors, 
with no significant difference between the enhancement seen 
at either receptor subtype, at ionotropic GABA type A recep-
tors expressed in X. laevis oocytes and at sites independent 
of the flumazenil-sensitive benzodiazepine binding site.103 
Subsequently, 6-methylflavanone (Figure 5) was also found 
to be a flumazenil-insensitive positive modulator of recom-
binant GABA type A receptors that, unlike 6-methylflavone, 
was subtype-selective, being a more efficacious positive 
modulator at α2β2γ2L receptors that at α1β2γ2L and α1β2 
receptors.104 6-Methylflavanone differs from 6-methylflavone 
in having a single rather than a double bond at C2–C3; hence, 
this bond is crucial to the observed subtype-selective efficacy 
of 6-methylflavanone. Two new 6-methylflavone derivatives 
were recently reported, ie, 2′-methoxy-6-methylflavone105 
and 3-hydroxy-2′-methoxy-6-methylflavone.106 2′-Methoxy-
6-methylflavone potentiated GABA at α2β1γ2L and all 
α1-containing GABA type A receptor subtypes. However, 
it directly activated α2β2/3γ2L GABA type A receptors 
without potentiating GABA. This activation was attenuated 
by bicuculline and gabazine, but not flumazenil, indicating 
a novel site. In mice, when administered intraperitoneally, it 
displayed anxiolytic-like effects, and at higher doses induced 
sedation. Like the in vitro data, the anxiolytic effects of 
2′-methoxy-6-methylflavone were not blocked by fluma-
zenil, a benzodiazepine antagonist, but were attenuated by 
pentylenetetrazole, a GABA type A channel blocker. These 
data imply that the anxiolytic effects are mediated via the 
GABAergic system, but not through the classical benzodi-
azepine binding site, despite 2′-methoxy-6-methylflavone 
Table 2 (Continued)
Flavonoid derivative Kia (μM) GABA  
ratiob
Pharmacological profile
Predictedb In vivo In vitro
2′-hydroxy 0.31101 ND ND Antagonist101 Neutralizing modulator101
6,2′-dihydroxy 0.04117 ND ND Partial inverse agonist117 Negative modulator117
2′-methoxy-6-methyl .100105 ND ND Partial agonist105 Positive modulator 
(α1 and α2β1γ2L subtypes) 
Allosteric activator 
(α2β2/3 and α2β2/3γ2L containing subtypes)105
3-hydroxy-2′-methoxy- 
6-methyl
.300106 ND ND Partial agonist106 Positive allosteric modulator  
(α2β2/3γ2L subtypes) 
Direct activation 
(α4β2/3γ subtypes)106
Notes: aKi ± standard error of the mean values are means of 3–5 independent determinations and estimate the inhibition of 3H-flunitrazepam binding to rat cerebral cortical 
synaptosomal membranes. The standard error of the mean varies between 6% and 13% of the absolute values listed. bThe pharmacological profile of ligands interacting 
in vitro with the benzodiazepine binding site can be predicted through the GABA ratios obtained in binding assays. These values are the ratio of Ki values of a competitive 
benzodiazepine binding site ligand measured in the presence or absence of GABA: ratios . 1 indicate compounds with agonistic profiles, ratios , 1 point to compounds with 
inverse agonistic profiles and ratios of about 1 indicate antagonistic profiles.110,111
Abbreviations: GABA, gamma aminobutyric acid; ND, not determined.
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weakly displacing flunitrazepam binding. These data would 
indicate that 2′-methoxy-6-methylflavone could bind to a 
novel as yet unidentified site on α2β2/3γ2L GABA type A 
receptors. 2′-Methoxy-6-methylflavone could serve as a tool 
to study the complex nature of the activation and modulation 
of GABA type A receptor subtypes. In addition, the synthetic 
flavonoid, 3-hydroxy-2′-methoxy-6-methylflavone was 
reported to be an anxiolytic without sedative and myorelaxant 
effects when administered intraperitoneally in mice, acting 
through positive allosteric modulation of the α2β2/3γ2L 
and direct activation of α4β2/3δ GABA type A receptor 
subtypes (Table 2).
Using 6-methylflavanone and EGCG as lead compounds, 
structure-activity studies led to the discovery of Fa131 
(2S,3R-3-acetoxy-4′-methoxyflavan) (Figure 5) as the most 
efficacious compound in a series of flavonol esters with 
positive modulatory activity of GABA type A receptors.107,108 
Interestingly, similar to barbiturates, Fa131 also acts as a 
weak partial agonist α1β2γ2L receptor and at higher doses 
exerts a negative modulatory effect.107 Fa131 is the first posi-
tive modulator to distinguish between the α2-subunit and 
α3-subunit containing GABA type A receptors, highlighting 
the potential of targeting flumazenil-insensitive allosteric 
sites in the search for new anxioselective drugs. In mice, 
when administered intraperitoneally, it induced an anxiolytic-
like action with no sedative or myorelaxant effects, and 
only weak barbiturate-potentiating effects on the loss of the 
righting reflex test. Recently there has been a report of a 
new flavan, Fa173 (2S;3S-3 acetoxy-3′,4′-dimethoxyflavan) 
(Figure 5), which neutralizes the potentiating actions of 
Fa131, etomidate, and loreclezole at α1β2 and α1β2γ2L 
GABA type A receptors expressed in X. laevis oocytes. 
Furthermore potentiation of high, but not low, concentrations 
of diazepam can be blocked by Fa173.109
A series of isoflavone derivatives was recently synthe-
sized, and their modulatory effect was evaluated on the 
α1β2γ2L GABA type A receptors expressed in X. laevis 
oocytes. This set of isoflavones acted as positive modula-
tors of GABA type A receptors and it was demonstrated 
that substitution of the A, B, and C rings plays an important 
role in determining GABA type A modulation activity. 
 Flumazenil-insensitive modulation by the isoflavones sug-
gested that these compounds might not bind to the benzodi-
azepine binding site.118
Since the first discovery of a flavonoid as a benzodiaz-
epine binding site ligand almost 30 years ago, an extensive 
collection of natural and synthetic flavonoids has been 
reported providing potential leads for new GABA type A 
receptor agents and they have already become drugs with 
beneficial effects in the central nervous system. The in vivo 
and in vitro actions of some flavonoids are more complex 
than a single action at the benzodiazepine binding site, and 
some evidence of a flavonoid site in GABA type A receptors 
is emerging. More studies are required in order to determine 
the precise site of action of these bioactive molecules on 
GABA type A receptors and to understand fully their mecha-
nisms of action as modulators of brain function. Also, further 
investigations of type specificity of flavonoids might lead to 
identification of flavonoids with selective pharmacological 
activity, thus providing a clinically interesting lead structure. 
Further, the concentrations of dietary flavonoids encountered 
in vivo are high enough to have pharmacological activity 
at receptors, and the evidence also supports localization of 
flavonoids within the brain.
In summary, flavonoids are prominent drugs in the treat-
ment of mental disorders, and can also be used as tools to 
study modulatory sites at GABA type A receptors and to 
develop GABA subtype-selective agents further.
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